BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 29868853)

  • 1. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
    Shiramoto M; Liu S; Shen Z; Yan X; Yamamoto A; Gillen M; Ito Y; Hall J
    Rheumatology (Oxford); 2018 Sep; 57(9):1602-1610. PubMed ID: 29868853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lesinurad: A Review in Hyperuricaemia of Gout.
    Deeks ED
    Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study.
    Stack AG; Han D; Goldwater R; Johansson S; Dronamraju N; Oscarsson J; Johnsson E; Parkinson J; Erlandsson F
    J Clin Endocrinol Metab; 2021 Apr; 106(5):e2347-e2356. PubMed ID: 33075806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
    Fleischmann R; Kerr B; Yeh LT; Suster M; Shen Z; Polvent E; Hingorani V; Quart B; Manhard K; Miner JN; Baumgartner S;
    Rheumatology (Oxford); 2014 Dec; 53(12):2167-74. PubMed ID: 24509406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study.
    Fleischmann R; Winkle P; Hall J; Valdez S; Liu S; Yan X; Hicks L; Lee C; Miner JN; Gillen M; Hernandez-Illas M
    RMD Open; 2018; 4(1):e000647. PubMed ID: 29657831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
    Liang N; Sun M; Sun R; Xu T; Cui L; Wang C; Ma L; Cheng X; Xue X; Sun W; Yuan X; Zhang H; Li H; He Y; Ji A; Wu X; Li C
    Arthritis Res Ther; 2019 Sep; 21(1):200. PubMed ID: 31477161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.
    Tan PK; Liu S; Gunic E; Miner JN
    Sci Rep; 2017 Apr; 7(1):665. PubMed ID: 28386072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers.
    Hall J; Gillen M; Yang X; Shen Z
    Clin Pharmacol Drug Dev; 2019 Feb; 8(2):179-187. PubMed ID: 29688628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout.
    Steinberg AS; Vince BD; Choi YJ; Martin RL; McWherter CA; Boudes PF
    J Rheumatol; 2017 Mar; 44(3):374-379. PubMed ID: 27980008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout.
    Kankam M; Hall J; Gillen M; Yang X; Shen Z; Lee C; Liu S; Miner JN; Walker S; Clauson V; Wilson D; Nguyen M
    J Clin Pharmacol; 2018 Sep; 58(9):1214-1222. PubMed ID: 29733447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor.
    Smith WB; Hall J; Berg JK; Kazimir M; Yamamoto A; Walker S; Lee CA; Shen Z; Wilson DM; Zhou D; Gillen M; Marbury TC
    Clin Drug Investig; 2018 Aug; 38(8):703-713. PubMed ID: 29949102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study.
    Dalbeth N; Jones G; Terkeltaub R; Khanna D; Fung M; Baumgartner S; Perez-Ruiz F
    Arthritis Res Ther; 2019 Jan; 21(1):8. PubMed ID: 30616614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial.
    Stack AG; Dronamraju N; Parkinson J; Johansson S; Johnsson E; Erlandsson F; Terkeltaub R
    Am J Kidney Dis; 2021 Apr; 77(4):481-489. PubMed ID: 33130235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A semi-mechanistic exposure-response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases.
    Leander J; Sunnåker M; Rekić D; Aksenov S; Eriksson UG; Johansson S; Parkinson J
    J Pharmacokinet Pharmacodyn; 2021 Aug; 48(4):525-541. PubMed ID: 33728547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
    Miner JN; Tan PK; Hyndman D; Liu S; Iverson C; Nanavati P; Hagerty DT; Manhard K; Shen Z; Girardet JL; Yeh LT; Terkeltaub R; Quart B
    Arthritis Res Ther; 2016 Oct; 18(1):214. PubMed ID: 27716403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials.
    Fitz-Patrick D; Roberson K; Niwa K; Fujimura T; Mori K; Hall J; Yan X; Shen Z; Liu S; Ito Y; Baumgartner S
    Mod Rheumatol; 2019 Nov; 29(6):1042-1052. PubMed ID: 30334639
    [No Abstract]   [Full Text] [Related]  

  • 17. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S50-6. PubMed ID: 21654270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and Commonly Used Drugs for Gout Treatment.
    Shen Z; Tieu K; Wilson D; Bucci G; Gillen M; Lee C; Kerr B
    Clin Pharmacol Drug Dev; 2017 Jul; 6(4):377-387. PubMed ID: 28074640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects.
    Shen Z; Gillen M; Miner JN; Bucci G; Wilson DM; Hall JW
    Drug Des Devel Ther; 2017; 11():2077-2086. PubMed ID: 28744099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males.
    Shen Z; Rowlings C; Kerr B; Hingorani V; Manhard K; Quart B; Yeh LT; Storgard C
    Drug Des Devel Ther; 2015; 9():3423-34. PubMed ID: 26170627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.